Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062233) THERAPEUTIC AGENT CONTAINING ISOLATED RECOMBINANT ONCOLYTIC POXVIRUS AND NK CELLS, APPLICATION THEREOF, KIT APPLYING SAME, AND METHOD FOR TREATING TUMORS AND/OR CANCER USING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062233 International Application No.: PCT/CN2018/093401
Publication Date: 04.04.2019 International Filing Date: 28.06.2018
IPC:
A61K 35/768 (2015.01) ,C12N 7/00 (2006.01) ,A61K 35/17 (2015.01) ,C07K 14/54 (2006.01)
[IPC code unknown for A61K 35/768]
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
54
Interleukins (IL)
Applicants:
杭州康万达医药科技有限公司 HANGZHOU CONVERD CO., LTD. [CN/CN]; 中国浙江省杭州市 余杭区仓前街道余杭塘路2959号4幢7层 7th Floor, Building #4, 2959 Yuhangtang Road, Yuhang District Hangzhou, Zhejiang 311121, CN
Inventors:
傅瑾 FU, Jin; CN
赵荣华 ZHAO, Ronghua; CN
张蓉 ZHANG, Rong; CN
王婷婷 WANG, Tingting; CN
陈霖 CHEN, Lin; CN
胡放 HU, Fang; CN
Agent:
北京天昊联合知识产权代理有限公司 TEE&HOWE INTELLECTUAL PROPERTY ATTORNEYS; 中国北京市 东城区建国门内大街28号民生金融中心D座10层丁业平 DING, Yeping, 10th Floor, Tower D Minsheng Financial Center 28 Jianguomennei Avenue Dongcheng District, Beijing 100005, CN
Priority Data:
201710882027.126.09.2017CN
Title (EN) THERAPEUTIC AGENT CONTAINING ISOLATED RECOMBINANT ONCOLYTIC POXVIRUS AND NK CELLS, APPLICATION THEREOF, KIT APPLYING SAME, AND METHOD FOR TREATING TUMORS AND/OR CANCER USING SAME
(FR) AGENT THÉRAPEUTIQUE CONTENANT UN POXVIRUS ONCOLYTIQUE RECOMBINANT ISOLÉ ET DES CELLULES NK, SON APPLICATION, KIT L'APPLIQUANT ET PROCÉDÉ DE TRAITEMENT DE TUMEURS ET/OU DE CANCER L'UTILISANT
(ZH) 包含分离的重组溶瘤痘病毒和NK细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
Abstract:
(EN) A therapeutic agent containing an isolated recombinant oncolytic poxvirus and NK cells, a kit applying the same, and a method for treating tumors and/or cancer using the same. The therapeutic agent comprises (a) a first pharmaceutical composition containing a recombinant oncolytic poxvirus; and (b) a second pharmaceutical composition containing NK cells. The recombinant oncolytic poxvirus is functionally deficient in a TK gene and a VGF gene, an exogenous IL-21 gene is integrated into the genome of the recombinant oncolytic poxvirus, and the IL-21 gene can be expressed in tumor cells. The recombinant oncolytic poxvirus can produce a synergistic effect on the oncolytic effect of an oncolytic virus and the anti-tumor immunostimulatory effect of the IL-21 gene. The combination of the recombinant oncolytic poxvirus and NK cells produces a further enhanced synergistic killing effect on tumors.
(FR) L'invention concerne un agent thérapeutique contenant un poxvirus oncolytique recombinant isolé et des cellules NK, un kit l'appliquant, et un procédé de traitement de tumeurs et/ou de cancer l'utilisant. L'agent thérapeutique comprend (a) une première composition pharmaceutique contenant un poxvirus oncolytique recombinant; et (b) une seconde composition pharmaceutique contenant des cellules NK. Le poxvirus oncolytique recombinant est fonctionnellement déficient en un gène TK et un gène VGF, un gène IL-21 exogène est intégré dans le génome du poxvirus oncolytique recombinant, et le gène IL-21 peut être exprimé dans des cellules tumorales. Le poxvirus oncolytique recombinant peut produire un effet synergique sur l'effet oncolytique d'un virus oncolytique et l'effet immunostimulant anti-tumoral du gène IL-21. La combinaison du poxvirus oncolytique recombinant et des cellules NK produit un effet de destruction synergique amélioré sur les tumeurs.
(ZH) 包含分离的重组溶瘤痘病毒和NK细胞的治疗剂、药盒,治疗肿瘤和/或癌症的方法。所述治疗剂包含(a)第一药物组合物,其包含重组溶瘤痘病毒;和(b)第二药物组合物,其包含NK细胞;所述重组溶瘤痘病毒是TK基因和VGF基因功能缺陷型的,并且该重组溶瘤痘病毒的基因组中整合有外源IL-21基因,并且该IL-21基因能够在肿瘤细胞中表达。所述重组溶瘤痘病毒能够使溶瘤病毒的溶瘤杀伤作用和IL-21的抗肿瘤免疫刺激作用产生协同效果。所述重组溶瘤痘病毒与NK细胞联用可产生进一步加强的协同杀伤肿瘤的作用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)